Effective obesity drugs were a long time coming, but they have arrived amid a flurry of other treatment innovations, from new migraine therapies to gene therapies for sickle cell disease. This, combined with the sheer size of the obesity market, is forcing payers to severely restrict reimbursement.
“We don’t routinely cover GLP-1 agonists” like Novo Nordisk Pharma AG(semaglutide) or Eli Lilly and Company’s Zepbound (tirzepatide)...